Despite the considerable amount of scientific research on human health, only few drugs are developed. The problem is especially excruciating in the case of cancer disease. In my study, I hope to refine our understanding about knowledge translation from scientific research to drug development in cancer disease. To this end, I distinguish the type of scientific research according to its degree of basicness (basic research, clinical investigation, clinical mix and clinical observation), and the stage of maturity of drug development (engagement and success stages), and the degree of radicalness of drug development. I also try to ascertain whether social capital embedded in drug development networks is an important channel to foster knowledge translation. To build indicators related to drug development, I collected data on cancer clinical trials. The preliminary results show that organizations involved in radical drug development and strong in social capital are more likely to develop successful drugs. My study will highlight the importance of knowledge translation from scientific research to drug development in the medical field, and will provide some suggestions to organizations and policy makers on how to improve drug development in the field of cancer disease

Trabajo presentado en la DRUID Academy Conference: ECONOMICS AND MANAGEMENT OF INNOVATION, TECHNOLOGY AND ORGANIZATIONS, celebrada en Aalborg (Dinamarca), del 16 al 18 de enero de 2019